文献速递前列腺癌

恩扎卢胺治疗阿比特龙联合泼尼松治疗后进展的mCRPC

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
PubMed 文献 · Eur Urol · 2017-08-23

多中心单臂开放标签研究纳入214例经阿比特龙联合泼尼松治疗≥24周后进展的mCRPC患者,口服恩扎卢胺160mg/d。中位影像学无进展生存期8.1个月(95%CI 6.1-8.3),中位总生存期未达到,未经确认的PSA缓解率27%(48/181),中位PSA进展时间5.7个月(95%CI 5.6-5.8)。部分患者仍有抗肿瘤活性。

要点

  • 经阿比特龙联合泼尼松治疗≥24周后进展的mCRPC患者中,恩扎卢胺中位影像学无进展生存期为8.1个月。
  • 未经确认的PSA缓解率为27%(48/181),中位PSA进展时间5.7个月。
  • 常见治疗中出现的不良事件为疲乏(32%)、食欲下降(25%)、乏力(18%)、背痛(17%)和关节痛(16%),未报告癫痫发作。

核心结论

  • 恩扎卢胺在部分经阿比特龙联合泼尼松治疗≥24周后进展的mCRPC患者中显示出抗肿瘤活性。
  • 多数患者观察到两种药物间的交叉耐药,但部分患者仍从恩扎卢胺治疗中获益。

研究设计与样本

  • 多中心、单臂、开放标签研究,纳入经阿比特龙联合泼尼松治疗≥24周后进展的mCRPC患者。
  • 共214例患者接受恩扎卢胺治疗,其中145例未接受过化疗。
  • 所有患者在试验期间维持去势治疗;允许既往化疗但非必需。
  • 患者口服恩扎卢胺160mg/d。

主要发现

  • 中位影像学无进展生存期为8.1个月(95%CI 6.1-8.3)。
  • 中位总生存期未达到。
  • 未经确认的PSA缓解率为27%(48/181)。
  • 中位PSA进展时间为5.7个月(95%CI 5.6-5.8)。
  • 最常见治疗中出现的不良事件为疲乏(32%)、食欲下降(25%)、乏力(18%)、背痛(17%)和关节痛(16%);未报告癫痫发作。

关键数值与推荐

  • 主要终点为影像学无进展生存期。
  • 次要终点包括总生存期、PSA缓解率和PSA进展时间,并评估安全性。
  • 采用Kaplan-Meier法对时间-事件终点进行描述性分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported. OBJECTIVE: To fulfil a regulatory postregistration commitment by evaluating the efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following abiraterone acetate plus prednisone treatment. DESIGN, SETTING, AND PARTICIPANTS: Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment. All patients maintained castration therapy during the trial. Prior chemotherapy was allowed but not required. INTERVENTION: Patients received enzalutamide 160mg/d orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was radiographic progression-free survival. Secondary endpoints were overall survival, prostate-specific antigen (PSA) response, and time-to-PSA progression. Safety data were also assessed. Kaplan-Meier methods were used to descriptively analyse time-to-event endpoints. RESULTS AND LIMITATIONS: Overall, 214 patients received enzalutamide treatment, 145 of whom were chemotherapy-naïve. Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached. Unconfirmed PSA response rate was 27% (48 of 181). Median time-to-PSA progression was 5.7 mo (95% confidence interval: 5.6-5.8). The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%). No seizures were reported. CONCLUSIONS: Enzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment. PATIENT SUMMARY: Patients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. Eur Urol. 2017. PMID: 28844372. doi:10.1016/j.eururo.2017.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。